Foghorn Therapeutics (FHTX) Competitors $5.88 +0.08 (+1.38%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$5.86 -0.01 (-0.26%) As of 07/16/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX vs. HROW, PAHC, ABCL, COGT, PHVS, NTLA, CVAC, AUPH, WVE, and CALTShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Cogent Biosciences (COGT), Pharvaris (PHVS), Intellia Therapeutics (NTLA), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. Its Competitors Harrow Phibro Animal Health AbCellera Biologics Cogent Biosciences Pharvaris Intellia Therapeutics CureVac Aurinia Pharmaceuticals WAVE Life Sciences Calliditas Therapeutics AB (publ) Foghorn Therapeutics (NASDAQ:FHTX) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Does the media favor FHTX or HROW? In the previous week, Harrow had 21 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 22 mentions for Harrow and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.89 beat Harrow's score of 0.59 indicating that Foghorn Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Foghorn Therapeutics Very Positive Harrow Positive Which has more risk and volatility, FHTX or HROW? Foghorn Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Is FHTX or HROW more profitable? Harrow has a net margin of -10.19% compared to Foghorn Therapeutics' net margin of -342.23%. Foghorn Therapeutics' return on equity of 0.00% beat Harrow's return on equity.Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-342.23% N/A -27.28% Harrow -10.19%-25.01%-4.27% Do insiders and institutionals hold more shares of FHTX or HROW? 61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 15.2% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate FHTX or HROW? Foghorn Therapeutics presently has a consensus target price of $12.13, suggesting a potential upside of 106.21%. Harrow has a consensus target price of $63.83, suggesting a potential upside of 84.76%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Foghorn Therapeutics is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, FHTX or HROW? Harrow has higher revenue and earnings than Foghorn Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$22.60M14.50-$86.62M-$1.36-4.32Harrow$199.61M6.35-$17.48M-$0.56-61.70 SummaryHarrow beats Foghorn Therapeutics on 9 of the 17 factors compared between the two stocks. Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$323.30M$2.90B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-4.3220.3628.1919.69Price / Sales14.50299.07442.3499.85Price / CashN/A42.3835.5357.53Price / Book-7.177.768.235.67Net Income-$86.62M-$55.11M$3.23B$257.51M7 Day Performance8.89%0.19%-0.57%-0.16%1 Month Performance22.76%10.80%6.66%9.89%1 Year Performance-7.69%-0.68%27.11%15.08% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics2.0968 of 5 stars$5.88+1.4%$12.13+106.2%-11.8%$323.30M$22.60M-4.32120Positive NewsHROWHarrow2.3866 of 5 stars$35.62+2.0%$63.83+79.2%+39.2%$1.31B$199.61M-63.61180Analyst RevisionPAHCPhibro Animal Health4.0323 of 5 stars$31.54+2.4%$24.40-22.6%+60.3%$1.28B$1.02B40.441,940ABCLAbCellera Biologics2.1175 of 5 stars$4.24+5.7%$8.75+106.4%+16.3%$1.27B$28.83M-7.57500Analyst ForecastHigh Trading VolumeCOGTCogent Biosciences3.5482 of 5 stars$11.09+1.0%$18.00+62.3%+24.8%$1.26BN/A-6.0380Insider TradeAnalyst RevisionHigh Trading VolumePHVSPharvaris1.3815 of 5 stars$23.80-5.3%$36.20+52.1%+24.1%$1.24BN/A-7.9130High Trading VolumeNTLAIntellia Therapeutics4.3998 of 5 stars$11.95+3.6%$33.37+179.2%-56.3%$1.24B$57.88M-2.28600CVACCureVac4.3742 of 5 stars$5.46flat$6.83+25.2%+53.9%$1.22B$579.18M5.93880Positive NewsAUPHAurinia Pharmaceuticals3.1669 of 5 stars$9.04+2.7%$11.50+27.2%+52.6%$1.22B$235.13M32.29300Positive NewsWVEWAVE Life Sciences4.5121 of 5 stars$7.84+1.8%$20.50+161.5%+30.6%$1.22B$108.30M-9.33240News CoverageAnalyst ForecastGap UpCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Harrow Competitors Phibro Animal Health Competitors AbCellera Biologics Competitors Cogent Biosciences Competitors Pharvaris Competitors Intellia Therapeutics Competitors CureVac Competitors Aurinia Pharmaceuticals Competitors WAVE Life Sciences Competitors Calliditas Therapeutics AB (publ) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FHTX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FHTX Stock Alerts